KENILWORTH (NJ) (dpa-AFX) - Thursday, Merck & Co., Inc. (MRK) announced that
Health Canada has approved Keytruda, also known as pembrolizumab, for the
treatment of adult patients with locally advanced unresectable or metastatic
biliary tract carcinoma when used alongside gemcitabine-based chemotherapy.

Biliary tract carcinoma is a rare and aggressive group of cancers affecting the
gallbladder and bile ducts.

The company said that the approval is based on the findings of the Phase 3
KEYNOTE-966 trial, showing a significant improvement in overall survival
compared to chemotherapy alone.

Keytruda was initially sanctioned in Canada in 2015 and is now prescribed for
various conditions such as advanced renal cell carcinoma, bladder cancer,
non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical
Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer,
esophageal cancer, triple-negative breast cancer, melanoma, and head and neck
squamous cell carcinoma.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX